Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-386.85K) by net assets ($-9.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LIMN net asset quality index to measure how much of total assets are equity-financed.
Liminatus Pharma, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Liminatus Pharma, Inc. Class A Common St to evaluate the quality of earnings relative to operating cash generation.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eminence Minerals Limited
AU:EMA
|
-0.112x |
|
Wide Open Agriculture Ltd
AU:WOA
|
-0.429x |
|
YY Group Holding Limited Class A Ordinary Shares
NASDAQ:YYGH
|
-0.093x |
|
Prolexus Bhd
KLSE:8966
|
-0.039x |
|
Intelligent Group Limited Ordinary Shares
NASDAQ:INTJ
|
-0.001x |
|
Strike Resources Ltd
AU:SRK
|
-0.102x |
|
Global Engine Group Holding Limited Ordinary Shares
NASDAQ:GLE
|
-0.028x |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
-0.195x |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Liminatus Pharma, Inc. Class A Common St market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-9.81 Million | $-9.96 Million | 1.015x | +418.60% |
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -37.43% |
| 2023-12-31 | $-10.69 Million | $-3.35 Million | 0.313x | +146.59% |
| 2022-12-31 | $1.29 Million | $-869.00K | -0.671x | -13974.82% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.